| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
No specific drug target; serves as a stable isotope-labeled internal standard and tracer for tyrosine metabolism studies. L-tyrosine is a precursor for catecholamine neurotransmitters.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled compound, L-Tyrosine-3,5-13C2 exhibits identical chemical properties to unlabeled L-tyrosine. The non-labeled L-tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex. It serves as a precursor for the synthesis of catecholamines (dopamine, norepinephrine, epinephrine), thyroid hormones, and melanin. |
| ln Vivo |
The non-labeled L-tyrosine is an amino acid used as a dietary supplement to support cognitive function under stress conditions, as well as a precursor for neurotransmitter synthesis. It is also used clinically in the treatment of tyrosine metabolism disorders such as tyrosinemia and as an adjunct in the management of phenylketonuria (PKU). However, it is not approved as a drug for other indications.
|
| Enzyme Assay |
Receptor binding assays are not applicable. Standard analytical protocols using L-Tyrosine-3,5-13C2 involve its use as an internal standard for LC-MS/MS or GC-MS quantification of L-tyrosine in biological matrices. Samples (plasma, urine, tissue homogenates) are processed by protein precipitation with acetonitrile or methanol, derivatized (e.g., with dansyl chloride or AQC for fluorescence detection), separated on a C18 column, and analyzed by MRM in positive ion mode.
|
| Cell Assay |
For metabolic studies, cultured cells (e.g., hepatocytes, neuronal cells, or tumor cells) are treated with L-Tyrosine-3,5-13C2 at concentrations of 50-500 uM for 1-24 hours. Cellular metabolites are extracted and analyzed by LC-MS to trace 13C incorporation into downstream metabolites including L-DOPA, dopamine, norepinephrine, epinephrine, thyroid hormones, and fumarate/acetoacetate via tyrosine metabolism pathways.
|
| Animal Protocol |
In vivo metabolic flux studies in rodents involve administration of L-Tyrosine-3,5-13C2 via oral gavage or intravenous injection (10-100 mg/kg). Blood samples are collected at multiple time points (0-8 hours). Tissues including liver, brain, adrenal glands, and thyroid may be harvested. Isotopic enrichment of tyrosine and its metabolites (tyramine, dopamine, norepinephrine, epinephrine) is quantified by LC-MS/MS to study catecholamine synthesis and tyrosine metabolism.
|
| ADME/Pharmacokinetics |
As an analytical internal standard, pharmacokinetic properties are not directly assessed. The non-labeled L-tyrosine is a naturally occurring amino acid with rapid absorption from the gastrointestinal tract via amino acid transporters. Its plasma concentration is tightly regulated and typically ranges from 50-100 uM. Tyrosine is metabolized primarily in the liver via the tyrosine aminotransferase pathway. Plasma half-life in humans is approximately 1-2 hours.
|
| Toxicity/Toxicokinetics |
Toxicity data for the labeled compound are not available as it is used only as an analytical standard at tracer concentrations. The non-labeled L-tyrosine is a naturally occurring amino acid essential for protein synthesis and is generally considered safe at physiological levels. Very high doses (>150 mg/kg) may cause gastrointestinal discomfort. Individuals with tyrosinemia should avoid tyrosine supplementation.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
|
| Additional Infomation |
L-Tyrosine-3,5-13C2 is a stable isotope-labeled compound used exclusively for research and bioanalytical applications. It serves as an essential internal standard for the accurate quantification of L-tyrosine in biological samples using mass spectrometry. This compound is valuable for pharmacokinetic studies of tyrosine-containing drugs and peptides, for metabolic studies of tyrosine metabolism disorders (tyrosinemia, alkaptonuria), and for studying catecholamine biosynthesis in neuroscience research. It is not a therapeutic agent.
|
| Molecular Formula |
C10H12O3
|
|---|---|
| Molecular Weight |
182.19
|
| Exact Mass |
183.08
|
| CAS # |
70479-98-0
|
| Related CAS # |
L-Tyrosine;60-18-4
|
| PubChem CID |
162642143
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
176
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=[13CH]C(=[13CH]C=C1C[C@@H](C(=O)O)N)O
|
| InChi Key |
OUYCCCASQSFEME-ALJHITAUSA-N
|
| InChi Code |
InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1/i3+1,4+1
|
| Chemical Name |
(2S)-2-amino-3-(4-hydroxy(3,5-13C2)cyclohexa-1,3,5-trien-1-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 4.81 mg/mL (26.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4888 mL | 27.4439 mL | 54.8878 mL | |
| 5 mM | 1.0978 mL | 5.4888 mL | 10.9776 mL | |
| 10 mM | 0.5489 mL | 2.7444 mL | 5.4888 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
